The Synergy of Carbon Ion Radiotherapy and Immunotherapy: A New Frontier in Oncology

The intersection of radiotherapy and immunology has emerged as a highly promising frontier: localized radiotherapy can act as an in-situ vaccine, triggering prompt systemic anti-tumor responses. Carbon ion radiotherapy (CIRT) outperforms conventional photon radiotherapy (XRT) by delivering a highly concentrated dose to the target volume while minimizing collateral damage to adjacent healthy structures and preserving peripheral immune tissues. Emerging preclinical and clinical data indicate that CIRT possesses ex-traordinary immunomodulatory potential. High-LET carbon ion irradiation strongly drives immunogenic cell death (ICD), promotes mature dendritic cell antigen presentation, and strongly upregulates the cGAS–STING signaling cascade, shifting the TME from a "cold" immunosuppressive state to a "hot" immunostimulatory environment. Recent find-ings also show that carbon ions potently trigger non-apoptotic cell death modalities, fer-roptosis, necroptosis, and autophagy, which amplify ICD. When combined with IT, this triggers a potent synergistic effect that targets both local tumor recurrence and distant me-tastases. However, clinical translation faces critical issues, including patient selection and optimal dosing and scheduling. This review synthesizes key preclinical breakthroughs and emerging clinical data on CIRT combined with IT, exploring the molecular mecha-nisms underlying the synergy of this combination. We also discuss perspectives and fu-ture directions needed to optimize this promising therapeutic strategy.